ACADIA Pharmaceuticals (FRA:DR6) Interest Expense : €0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ACADIA Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was € 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ACADIA Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was € 14.0 Mil. ACADIA Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was € 0.0 Mil. GuruFocus does not calculate ACADIA Pharmaceuticals's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ACADIA Pharmaceuticals Interest Expense Historical Data

The historical data trend for ACADIA Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Interest Expense Chart

ACADIA Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

ACADIA Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

ACADIA Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

ACADIA Pharmaceuticals (FRA:DR6) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ACADIA Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was €0.0 Mil. Its Operating Income for the three months ended in Mar. 2024 was €14.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €45.3 Mil.

ACADIA Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GuruFocus does not calculate ACADIA Pharmaceuticals's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. ACADIA Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

ACADIA Pharmaceuticals (FRA:DR6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ACAD:USA

Address

12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130

Website

https://www.acadia-pharm.com

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

ACADIA Pharmaceuticals (FRA:DR6) Headlines

No Headlines